Significant ETF Inflows: SPLG, XOM, WFC, ABT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: NASDAQ.COM
SPLG Share Price Analysis: SPLG's current share price is $75.74, with a 52-week low of $56.6699 and a high of $76.025.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting their underlying holdings.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 101.050
Low
136.00
Averages
148.11
High
169.00
Current: 101.050
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Expected to Report Modest Q1 Growth
- Earnings Expectations: Abbott is set to report its Q1 earnings on April 16, with EPS expected to rise 5.5% to $1.15 and revenue projected to increase 6.2% to $11 billion, although analysts express caution with multiple downward revisions in both EPS and revenue estimates.
- Nutrition Business Challenges: The Nutrition segment experienced a 9% year-over-year sales decline in Q4 due to market share loss and the loss of a significant contract, with CEO Robert Ford forecasting continued challenges in the first half, but potential growth in the second half from the launch of eight new products.
- Acquisition Impact: Abbott's acquisition of Exact Sciences, which closed in March, is anticipated to enhance Abbott's competitive position in the $60 billion U.S. cancer diagnostics market and may help reverse the negative organic growth trend in its diagnostics business.
- Performance History: Over the past two years, Abbott has beaten EPS estimates 88% of the time and revenue estimates 50% of the time, indicating a solid performance track record despite current challenges.
See More
S&P 500 Hits New Yearly High as Tech Stocks Rally
- S&P 500 Performance: The S&P 500 reached a new intraday high on Wednesday, briefly surpassing 7,000 points, indicating a rebound from the Iran war sell-off, and needs to close above 6,978.6 to break its record closing high set on January 27.
- Tech Stock Strength: Major tech stocks like Apple, Meta, Broadcom, Tesla, and Microsoft propelled the index higher, while beaten-down enterprise software names such as Salesforce and ServiceNow extended their rebounds from multiyear lows, showcasing a robust recovery in the tech sector.
- Industrial Sector Pressure: The industrial sector was the worst performer in the S&P 500, with Barclays analyst highlighting that recent changes in Section 232 metal tariffs may have a larger-than-expected impact on the group, necessitating close monitoring of upcoming industrial earnings reports.
- CoreWeave Major Deal: CoreWeave announced a significant partnership with Jane Street, committing approximately $6 billion for access to next-generation computing capabilities, illustrating the broad impact of AI technology across various industries, with Nvidia's AI platform emerging as the technology of choice.
See More
Abbott Laboratories Q1 Earnings Preview
- Earnings Release Date: Abbott Laboratories is set to report its Q1 earnings on April 16, with an expected EPS of $1.15 and revenue of $11 billion, which could bolster investor confidence and potentially drive stock price appreciation.
- Acquisition Impact: Following the acquisition of Exact Sciences, Abbott's stock rose by 0.4%, indicating a positive market reaction that may enhance Abbott's competitive edge in the precision medicine sector.
- Market Expectations: Analysts are generally optimistic about Abbott's earnings performance, anticipating that strong revenue and profitability will further solidify its leadership position in the healthcare industry, particularly in the growing diagnostics and therapeutics markets.
- Strategic Positioning: By acquiring Exact Sciences, Abbott not only expands its product portfolio but also positions itself to enhance overall operational efficiency through technology integration, laying a solid foundation for future growth.
See More
Abbott Laboratories Ordered to Pay $70M in Baby Formula Case
- Increased Damages: A Chicago jury has raised the total damages Abbott Laboratories must pay to $70 million in a case alleging its baby formula caused necrotizing enterocolitis in preterm infants, which includes $53 million in compensatory damages and $17 million in punitive damages, reflecting the jury's strong disapproval of the company's alleged concealment of product risks.
- Company's Disagreement: Abbott has stated it disagrees with the verdict and plans to appeal, emphasizing that “science was ignored in this case,” and warning that the verdict could jeopardize vital options for doctors and vulnerable infants, indicating the company's concerns about future legal risks.
- Legal Litigation Risks: This verdict marks Abbott's second trial loss amid over 1,700 similar lawsuits, potentially costing the company billions in additional damages, which further exacerbates its financial and reputational risks in the market.
- Market Reaction: The ruling may negatively impact Abbott's stock price, prompting investors to closely monitor how the company addresses this legal challenge in upcoming earnings reports and its potential effects on business operations.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
Market Pullback Risk Grows, Investment Strategy Adjustments
- Market Pullback Risk: Stocks edged lower on Friday, putting the S&P 500's seven-day winning streak at risk, as profit-taking emerged after a strong week where the index rose approximately 3.5%, indicating cautious market sentiment.
- Target Price Adjustments: We raised Dover's price target from $220 to $230, anticipating growth across all its business segments in 2026, while noting its limited exposure to the Middle East, which underscores its robust growth potential.
- Strong Demand Outlook: Lumentum's CEO indicated the company is nearly sold out of optical components through 2028, suggesting strong demand, leading to an increase in Corning's price target from $160 to $180, reflecting its pricing power in the optical fiber market for data centers.
- Software Stock Pressure: We lowered the price targets for Salesforce and Microsoft to $215 and $500, respectively, due to ongoing pressure from AI threats in the enterprise software market, which is expected to impact their price-to-earnings multiples, reflecting a cautious outlook on software stocks.
See More
Abbott Laboratories Expected to Report Modest Q1 Growth
- Earnings Expectations: Abbott is set to report its Q1 earnings on April 16, with EPS expected to rise 5.5% to $1.15 and revenue projected to increase 6.2% to $11 billion, although analysts express caution with multiple downward revisions in both EPS and revenue estimates.
- Nutrition Business Challenges: The Nutrition segment experienced a 9% year-over-year sales decline in Q4 due to market share loss and the loss of a significant contract, with CEO Robert Ford forecasting continued challenges in the first half, but potential growth in the second half from the launch of eight new products.
- Acquisition Impact: Abbott's acquisition of Exact Sciences, which closed in March, is anticipated to enhance Abbott's competitive position in the $60 billion U.S. cancer diagnostics market and may help reverse the negative organic growth trend in its diagnostics business.
- Performance History: Over the past two years, Abbott has beaten EPS estimates 88% of the time and revenue estimates 50% of the time, indicating a solid performance track record despite current challenges.
See More
S&P 500 Hits New Yearly High as Tech Stocks Rally
- S&P 500 Performance: The S&P 500 reached a new intraday high on Wednesday, briefly surpassing 7,000 points, indicating a rebound from the Iran war sell-off, and needs to close above 6,978.6 to break its record closing high set on January 27.
- Tech Stock Strength: Major tech stocks like Apple, Meta, Broadcom, Tesla, and Microsoft propelled the index higher, while beaten-down enterprise software names such as Salesforce and ServiceNow extended their rebounds from multiyear lows, showcasing a robust recovery in the tech sector.
- Industrial Sector Pressure: The industrial sector was the worst performer in the S&P 500, with Barclays analyst highlighting that recent changes in Section 232 metal tariffs may have a larger-than-expected impact on the group, necessitating close monitoring of upcoming industrial earnings reports.
- CoreWeave Major Deal: CoreWeave announced a significant partnership with Jane Street, committing approximately $6 billion for access to next-generation computing capabilities, illustrating the broad impact of AI technology across various industries, with Nvidia's AI platform emerging as the technology of choice.
See More
Abbott Laboratories Q1 Earnings Preview
- Earnings Release Date: Abbott Laboratories is set to report its Q1 earnings on April 16, with an expected EPS of $1.15 and revenue of $11 billion, which could bolster investor confidence and potentially drive stock price appreciation.
- Acquisition Impact: Following the acquisition of Exact Sciences, Abbott's stock rose by 0.4%, indicating a positive market reaction that may enhance Abbott's competitive edge in the precision medicine sector.
- Market Expectations: Analysts are generally optimistic about Abbott's earnings performance, anticipating that strong revenue and profitability will further solidify its leadership position in the healthcare industry, particularly in the growing diagnostics and therapeutics markets.
- Strategic Positioning: By acquiring Exact Sciences, Abbott not only expands its product portfolio but also positions itself to enhance overall operational efficiency through technology integration, laying a solid foundation for future growth.
See More
Abbott Laboratories Ordered to Pay $70M in Baby Formula Case
- Increased Damages: A Chicago jury has raised the total damages Abbott Laboratories must pay to $70 million in a case alleging its baby formula caused necrotizing enterocolitis in preterm infants, which includes $53 million in compensatory damages and $17 million in punitive damages, reflecting the jury's strong disapproval of the company's alleged concealment of product risks.
- Company's Disagreement: Abbott has stated it disagrees with the verdict and plans to appeal, emphasizing that “science was ignored in this case,” and warning that the verdict could jeopardize vital options for doctors and vulnerable infants, indicating the company's concerns about future legal risks.
- Legal Litigation Risks: This verdict marks Abbott's second trial loss amid over 1,700 similar lawsuits, potentially costing the company billions in additional damages, which further exacerbates its financial and reputational risks in the market.
- Market Reaction: The ruling may negatively impact Abbott's stock price, prompting investors to closely monitor how the company addresses this legal challenge in upcoming earnings reports and its potential effects on business operations.
See More
Health Care Stocks Decline 1.1% on NYSE
- Healthcare Sector Weakness: The NYSE Health Care Index fell by 1.1% late Friday afternoon, indicating a decline in market confidence towards the healthcare sector, which may influence short-term investor decisions.
- Market Sentiment Deterioration: The drop in healthcare stocks could be linked to overall market sentiment, as increasing uncertainty about economic prospects leads to capital outflows from the healthcare sector, affecting stock performance of related companies.
- Industry Impact Assessment: The decline in the healthcare sector may negatively affect the financing capabilities and future investment plans of related companies, especially in the current economic environment where firms may face higher borrowing costs.
- Investor Focus Shift: As healthcare stocks decline, investors may shift their attention to other sectors with greater growth potential, further shrinking the market share of healthcare stocks and impacting the long-term development of the industry.
See More
Market Pullback Risk Grows, Investment Strategy Adjustments
- Market Pullback Risk: Stocks edged lower on Friday, putting the S&P 500's seven-day winning streak at risk, as profit-taking emerged after a strong week where the index rose approximately 3.5%, indicating cautious market sentiment.
- Target Price Adjustments: We raised Dover's price target from $220 to $230, anticipating growth across all its business segments in 2026, while noting its limited exposure to the Middle East, which underscores its robust growth potential.
- Strong Demand Outlook: Lumentum's CEO indicated the company is nearly sold out of optical components through 2028, suggesting strong demand, leading to an increase in Corning's price target from $160 to $180, reflecting its pricing power in the optical fiber market for data centers.
- Software Stock Pressure: We lowered the price targets for Salesforce and Microsoft to $215 and $500, respectively, due to ongoing pressure from AI threats in the enterprise software market, which is expected to impact their price-to-earnings multiples, reflecting a cautious outlook on software stocks.
See More
